1. Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. N Engl J Med. 2016; 375:2246-54.,2. Escudier BJ, Rini BI, Martini FJ, et al. Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma (RCC): Validation of the 16-gene Recurrence Score in stage III patients. J Clin Oncol 35, 2017 (suppl; abstr 4508).
ECCO 2017: Grote verschillen in Nederland bij opvolgen behandelrichtlijnen kanker
jan 2017 | Borstkanker, Longoncologie, Maag-darm-leveroncologie, Uro-oncologie